DBV Technologies reveals promising new results for VIASKIN Peanut

DBV Technologies presented encouraging additional results from the Phase 3 VITESSE study at the AAAAI Annual Meeting in Philadelphia. The data show that approximately 83% of children treated with the VIASKIN Peanut patch increased their response dose at 12 months, compared to 48% in the placebo group. Furthermore, 60% increased this dose by at least two levels, compared to 23% in the placebo group.

The study, evaluating the efficacy of VIASKIN Peanut in children with peanut allergy, demonstrated a significant difference between the treated and placebo groups, with a primary endpoint exceeding the predefined threshold. Analyses confirmed the patch's tolerability, with primarily mild local reactions.

These results reinforce hopes that VIASKIN Peanut will become a therapeutic option for children with peanut allergies, with an application for authorization expected to be submitted to the FDA in the first half of 2026.